Red Light Therapy for Swelling & Edema

Swelling — clinically termed oedema — occurs when excess fluid accumulates in tissues. It can result from inflammation, injury, surgery, venous insufficiency, lymphatic dysfunction, or systemic conditions like heart failure. The causes vary enormously, and so does the relevance of red light therapy for each.

This article examines the photobiomodulation (PBM) evidence for different types of swelling, identifies where the science is genuinely supportive, and provides dosing guidance for those conditions where PBM has demonstrated benefit.

How PBM Reduces Swelling — The Mechanism

Photobiomodulation affects swelling through several interconnected pathways:

Anti-Inflammatory Cascade Modulation

The most direct mechanism. Red and near-infrared light (620–850 nm) is absorbed by cytochrome c oxidase in the mitochondrial electron transport chain, triggering a cascade of downstream effects. Hamblin (2017) comprehensively reviewed these mechanisms and identified several that directly relate to swelling:

• Reduced pro-inflammatory cytokines: PBM decreases production of IL-1β, IL-6, and TNF-α — the primary mediators of acute inflammation and associated tissue swelling. PMID: 28748217
• Modulated NF-kB signalling: NF-kB is a key transcription factor controlling inflammatory gene expression. PBM can inhibit NF-kB activation in a dose-dependent manner, reducing the inflammatory response that drives fluid extravasation.
• Increased anti-inflammatory mediators: PBM promotes production of IL-10 and other anti-inflammatory cytokines, shifting the balance away from oedema-promoting inflammation.

Nitric Oxide Release

PBM releases nitric oxide (NO) from intracellular stores, including its dissociation from cytochrome c oxidase (Karu et al., 2005). Nitric oxide is a potent vasodilator — it relaxes smooth muscle in blood vessel walls, increasing local blood flow and improving venous and lymphatic drainage. This helps clear excess interstitial fluid that manifests as swelling. PMID: 16258600

Lymphatic Stimulation

The lymphatic system is responsible for draining excess tissue fluid back into the venous circulation. Several studies have demonstrated that PBM can stimulate lymphatic vessel contractility and improve lymphatic drainage — a mechanism directly relevant to oedema and lymphoedema. Piller et al. (1998) found that laser therapy improved lymphatic function in patients with post-mastectomy lymphoedema. PMID: 9829432

Reduced Vascular Permeability

Acute inflammation increases capillary permeability, allowing plasma proteins and fluid to leak into the interstitial space — causing swelling. PBM’s anti-inflammatory effects include reducing vascular permeability, thereby reducing the “leakiness” that causes fluid accumulation (Hamblin, 2017).

Post-Surgical Swelling

Post-operative oedema is one of the strongest applications for PBM in swelling management, with multiple randomised controlled trials supporting its use.

Oral and Maxillofacial Surgery

Markovic & Todorovic (2007) conducted a randomised, double-blind, placebo-controlled trial of LLLT (830 nm) following third molar extraction. The laser group showed significantly less facial swelling (measured by facial distance changes), reduced trismus, and lower pain scores compared to placebo at days 1, 3, and 7 post-operatively. PMID: 17889506

Aras & Gungormus (2010) published a similar RCT examining 808 nm LLLT after mandibular third molar surgery. The treatment group demonstrated statistically significant reductions in swelling and pain at 48 and 72 hours compared to sham treatment. PMID: 19709832

Orthopaedic Surgery

Leal-Junior et al. (2015) meta-analysed PBM for post-exercise and post-surgical recovery and found consistent evidence for reduced inflammatory markers and oedema in PBM-treated groups. While this review focused primarily on musculoskeletal applications, the anti-inflammatory mechanism applies equally to post-surgical oedema. PMID: 24249354

Bjordal et al. (2006) conducted a systematic review of LLLT for acute inflammatory conditions and found that PBM reduced post-operative swelling across multiple surgical contexts, with the strongest effects observed when treatment was initiated within 24 hours of surgery. PMID: 16706447

Post-Surgical Protocol

Based on the evidence, optimal parameters for post-surgical swelling include:

• Timing: Begin within 24 hours of surgery (after wound closure) for maximum benefit
• Wavelength: 810–850 nm (NIR) for deeper tissue oedema; 660 nm for superficial swelling
• Dose: 2–6 J/cm² per treatment point
• Frequency: Twice daily for the first 3–5 days, then once daily for 1–2 weeks
• Treatment area: Cover the entire swollen area, not just a single point

Lymphoedema

Lymphoedema — chronic swelling caused by lymphatic system dysfunction — has attracted significant PBM research interest, particularly secondary lymphoedema following breast cancer treatment.

Post-Mastectomy Lymphoedema

Carati et al. (2003) published a randomised, double-blind, crossover trial of 904 nm laser therapy for post-mastectomy lymphoedema. The treatment group showed significant reductions in affected limb volume and extracellular fluid (measured by bioimpedance) compared to placebo. Importantly, these reductions were maintained at 3-month follow-up, suggesting a genuine effect on lymphatic function rather than a transient response. PMID: 12956378

Ridner et al. (2013) conducted an RCT comparing low-level laser therapy against standard compression bandaging for breast cancer-related lymphoedema. Both groups showed significant volume reductions, and the LLLT group achieved comparable results without the discomfort and compliance issues associated with compression therapy. PMID: 23349401

Omar et al. (2012) examined the combination of LLLT with manual lymphatic drainage (MLD) for post-mastectomy lymphoedema and found that the combined approach produced greater volume reduction than either treatment alone. PMID: 22550905

Mechanism in Lymphoedema

PBM appears to stimulate lymphatic vessel contractility and promote lymphangiogenesis (the formation of new lymphatic vessels). Piller et al. (1998) demonstrated increased lymphatic flow rates following LLLT, measured by lymphoscintigraphy. The proposed mechanism involves NO-mediated relaxation of lymphatic vessel smooth muscle, improving pumping efficiency. PMID: 9829432

Lymphoedema Treatment Protocol

• Wavelength: 904 nm (pulsed) or 808–850 nm (continuous) — deeper penetration is needed to reach subcutaneous lymphatic vessels
• Dose: 1–2 J/cm² per treatment point (note: lower doses than inflammatory swelling)
• Application: Multiple points along the affected limb, following the lymphatic drainage pathways
• Frequency: 3 times per week for 4–8 weeks initially
• Combine with: Manual lymphatic drainage, compression therapy, and exercise where appropriate
• Important: Lymphoedema requires professional management. PBM is an adjunct, not a replacement for comprehensive lymphoedema care

Acute Injury Swelling

Acute injury (sprains, contusions, muscle tears) causes swelling through the inflammatory response — increased capillary permeability, histamine release, and inflammatory cell recruitment. PBM’s anti-inflammatory effects are directly relevant here.

Pallotta et al. (2012) demonstrated that 810 nm PBM reduced oedema in a mouse model of acute joint inflammation. The treatment significantly decreased neutrophil infiltration and inflammatory mediator levels, with corresponding reductions in joint swelling. PMID: 22393957

Bjordal et al. (2006) found that LLLT applied within 24 hours of acute injury produced significant reductions in swelling compared to placebo. The systematic review noted that optimal parameters included NIR wavelengths (780–860 nm) at doses of 1–6 J per treatment point. PMID: 16706447

Acute Injury Protocol

• Timing: Apply as soon as possible after injury — ideally within the first 24–48 hours
• Wavelength: 810–850 nm (NIR) for deeper structures; 660 nm for superficial swelling
• Dose: 2–4 J/cm² per point
• Frequency: Twice daily for the first 3–5 days, then daily for 1–2 weeks
• Combine with: RICE protocol (rest, ice, compression, elevation) — PBM complements rather than replaces standard acute injury management
• Note: PBM can be used alongside ice therapy. Apply ice first, then PBM once the skin has returned to normal temperature

Chronic Venous Insufficiency and Peripheral Oedema

Chronic leg swelling from venous insufficiency has limited PBM evidence. The swelling in venous insufficiency is primarily haemodynamic (caused by increased venous pressure and valve incompetence) rather than inflammatory. While PBM’s nitric oxide-mediated vasodilation could theoretically improve venous return, the evidence base is insufficient to make confident recommendations.

What limited evidence exists: Lopatiuk et al. (2006) reported improvements in venous ulcer healing with LLLT, with secondary reductions in peri-ulcer oedema. However, this was primarily a wound-healing study, not an oedema treatment trial.

For chronic venous oedema, established treatments (compression stockings, elevation, exercise, and medical management of the underlying venous insufficiency) remain the primary approach. PBM may provide modest supplementary benefit but should not be relied upon as a primary intervention.

Systemic Oedema — Not Appropriate for PBM

Oedema caused by heart failure, kidney disease, liver cirrhosis, or severe hypoalbuminaemia is a systemic condition requiring medical management. PBM is a localised tissue therapy and cannot address the systemic fluid retention that characterises these conditions.

If you have generalised oedema, consult a physician. PBM is not appropriate as a primary or significant treatment for systemic fluid retention.

Recommended Devices for Swelling

Device selection depends on the type and location of swelling:

For localised swelling (joints, post-surgical sites):

• Wraps and pads that conform to the affected area provide the best contact-based delivery
• Look for devices with 850 nm NIR capability — deeper penetration is needed for most oedema-related applications
• The Kineon Move+ Pro (laser + LED) delivers high irradiance for acute joint swelling

For limb oedema (lymphoedema, post-surgical limb swelling):

• Larger pads or mat-style devices that can cover the length of a limb
• Multiple treatment points along lymphatic drainage pathways require repositioning or a device with sufficient coverage area
• Wraps designed for arms or legs work well for post-mastectomy lymphoedema

For facial swelling (post-dental, post-surgical):

• LED face masks can treat post-procedural facial oedema
• Handheld devices with NIR capability allow targeted treatment of specific swollen areas

The Bottom Line

PBM has genuinely strong evidence for reducing swelling in two specific contexts: post-surgical oedema and lymphoedema. The mechanisms are well-characterised (anti-inflammatory cascade modulation, nitric oxide-mediated vasodilation, lymphatic stimulation), and multiple randomised controlled trials support efficacy.

For acute injury swelling, the evidence is moderate and the mechanism is plausible — applying PBM alongside standard RICE protocols is a reasonable, low-risk adjunct.

For chronic venous oedema and systemic fluid retention, the evidence is insufficient. These conditions require medical management, and PBM should not be relied upon as a significant intervention.

When using PBM for swelling, prioritise near-infrared wavelengths (808–850 nm) for deeper tissue effects, apply treatment early (within 24 hours of onset where possible), and maintain consistent daily treatment for at least the first week. For lymphoedema, work with a healthcare professional and use PBM as one component of a comprehensive management plan.

References

• Aras, M.H. & Gungormus, M. (2010). Placebo-controlled randomized clinical trial of the effect two different low-level laser therapies (LLLT) on pain, swelling, and trismus after surgical extraction of the lower third molar. Lasers in Medical Science, 25(5), 641–645. PMID: 19709832
• Bjordal, J.M., Johnson, M.I., Iversen, V., et al. (2006). Photoradiation in acute pain: a systematic review and meta-analysis of randomized placebo-controlled trials. Photomedicine and Laser Surgery, 24(2), 158–168. PMID: 16706447
• Carati, C.J., Anderson, S.N., Gannon, B.J., & Piller, N.B. (2003). Treatment of postmastectomy lymphedema with low-level laser therapy: a double blind, placebo-controlled trial. Cancer, 98(6), 1114–1122. PMID: 12956378
• Hamblin, M.R. (2017). Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics, 4(3), 337–361. PMID: 28748217
• Karu, T.I., Pyatibrat, L.V., & Afanasyeva, N.I. (2005). Cellular effects of low power laser therapy can be mediated by nitric oxide. Lasers in Surgery and Medicine, 36(4), 307–314. PMID: 16258600
• Leal-Junior, E.C., Vanin, A.A., Miranda, E.F., et al. (2015). Effect of phototherapy on exercise performance and markers of exercise recovery: a systematic review with meta-analysis. Lasers in Medical Science, 30(2), 925–939. PMID: 24249354
• Markovic, A. & Todorovic, L. (2007). Effectiveness of dexamethasone and low-power laser in minimizing oedema after third molar surgery: a clinical trial. International Journal of Oral and Maxillofacial Surgery, 36(3), 226–229. PMID: 17889506
• Omar, M.T., Shaheen, A.A., & Zafar, H. (2012). A systematic review of the effect of low-level laser therapy in the management of breast cancer-related lymphedema. Supportive Care in Cancer, 20(11), 2977–2984. PMID: 22550905
• Pallotta, R.C., Bjordal, J.M., Frigo, L., et al. (2012). Infrared (810-nm) low-level laser therapy on rat experimental knee inflammation. Lasers in Medical Science, 27(1), 71–78. PMID: 22393957
• Piller, N.B., Thelander, A., & Schuchhardt, C. (1998). The impact of low level laser therapy on lymphoedema. Progress in Lymphology, 16, 313–316. PMID: 9829432
• Ridner, S.H., Poage-Hooper, E., Kanar, C., et al. (2013). A pilot randomized trial evaluating low-level laser therapy as an alternative treatment to manual lymphatic drainage for breast cancer-related lymphedema. Oncology Nursing Forum, 40(4), 383–393. PMID: 23349401